Please assess the completion status of the following clinical trial:

Trial Title: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.~* All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).~* All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.~* All participants must have adequate organ function.~* Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.~Exclusion Criteria:~* All participants with non-secretory MM~* All participants with known auto-immune disease~* All participants with history of life-threatening toxicity related to prior immune therapy.~* All participants with active graft versus host disease after allogeneic stem cell transplantation.~* All participants with active, unstable cardiovascular function.~* All participants with active infection requiring systemic therapy.~* All participants with hypersensitivity to any of the treatments.~* All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Participants will receive EOS884448 (Type: EXPERIMENTAL): EOS884448 will be administered
- B: Participants will receive EOS884448 and iberdomide (Type: EXPERIMENTAL): EOS884448 and iberdomide will be administered
- C: Participants will receive EOS884448, iberdomide and dexamethasone (Type: EXPERIMENTAL): EOS884448, iberdomide and dexamethasone will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).